IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.62
+3.33%Oct 12, 2026, 23:35 UTC
Kuehn Law, PLLC said it is investigating whether Immunovant officers and directors breached fiduciary duties to shareholders through potential self-dealing.
Source:Sep 25, 2026, 17:55 UTC
SueWallSt notified investors of a pending investigation into potential securities law violations by Immunovant on behalf of IMVT investors who lost money.
Source:Sep 23, 2026, 11:00 UTC
Immunovant announced topline results from Period 1 of its proof-of-concept trial of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus, which did not achieve statistical significance on the primary endpoint of CLASI-A percent change from baseline at Week 12 and did not meet the company's internal bar to continue development in CLE.
Aug 18, 2026, 07:45 UTC
Immunovant, Inc. shares reached a new 52-week high of $43.89 during mid-day trading on Tuesday, last trading at $43.71 with a volume of 1,216,514 shares, after closing at $41.82.
Source:Aug 6, 2026, 00:00 UTC
Immunovant, Inc. reported its Q1 2026 financial results, with a GAAP net loss of $153.2 million and diluted EPS of -$0.75.
Source: